73 results
8-K
EX-99.2
SAVA
Cassava Sciences Inc
22 Nov 22
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
12:49pm
or potential health benefits of its product candidates, the severity and duration of health care precautions given the COVID-19 pandemic and unanticipated
8-K
EX-99.1
SAVA
Cassava Sciences Inc
22 Nov 22
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
12:49pm
health benefits of its product candidates, the severity and duration of health care precautions given the COVID-19 pandemic and unanticipated impacts
8-K
EX-99.1
SAVA
Cassava Sciences Inc
7 Nov 22
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
9:09am
the specificity, safety, efficacy or potential health benefits of our product candidates, the severity and duration of health care precautions given
8-K
SAVA
Cassava Sciences Inc
27 Oct 22
Cassava Sciences Announces Expansion of Leadership Team
4:03pm
in health care, private practice and government. He joins Cassava Sciences from Alcon Inc., a publicly traded medical company, where he served
8-K
EX-99.1
i53s58d6ptshnm
27 Oct 22
Cassava Sciences Announces Expansion of Leadership Team
4:03pm
8-K
EX-99.1
c5d4r737lm
3 Aug 22
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study
9:25am
8-K
EX-99.1
agq8 9vkooxe
5 May 22
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
9:04am
8-K
EX-99.1
vrw i0rpw91
28 Feb 22
Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates
12:00am
8-K
EX-99.1
ncucnmk8k
10 Nov 21
Cassava Sciences Reports Third Quarter 2021 Financial Results
9:10am
8-K
EX-99.2
qzt2bno10dr3cgjoso
3 Aug 21
Regulation FD Disclosure
4:36pm
8-K
EX-99.1
0wwldxnvl
3 Aug 21
Regulation FD Disclosure
4:36pm
8-K
EX-99.3
fdan7 y83c6ey
3 Aug 21
Regulation FD Disclosure
4:36pm
8-K
EX-99.1
idj6bhb
3 Aug 21
Cassava Sciences Reports Second Quarter 2021 Financial Results
8:45am
8-K
EX-99.1
lkqbe15d89e1yb30u3i
21 Jun 21
Entry into a Material Definitive Agreement
4:46pm
8-K
EX-99.1
2vth9a4
14 Jun 21
Cassava Sciences Announces the Appointment of
4:14pm
8-K
EX-99.1
jhunu6vgdfr6l46of
21 Apr 21
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
8:45am
8-K
EX-99.1
wj9j29g9 8atutfe
11 Mar 21
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
4:59pm